An­oth­er death mars Ab­b­Vie's lat­est batch of promis­ing da­ta for its star rheuma­toid arthri­tis drug

Ab­b­Vie $AB­BV is one step clos­er to achiev­ing its goal of rolling out a close­ly-watched drug for rheuma­toid arthri­tis as the third late-stage study in the pro­gram de­liv­ered an­oth­er round of promis­ing re­sults. But it’s still be­ing dogged by safe­ty is­sues that may yet come back to haunt the ef­fort.

Re­searchers say that the JAK-1 in­hibitor upadac­i­tinib (bet­ter known as ABT-494) hand­i­ly beat out methotrex­ate as a monother­a­py among pa­tients who weren’t ad­e­quate­ly re­spond­ing to the stan­dard gener­ic. The key fig­ures:

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.